Quantitative analysis of bone marrow fibrosis highlights heterogeneity in myelofibrosis and augments histological assessment: An Insight from a phase II clinical study of zinpentraxin alfa

• Hosuk Ryou,
• Korsuk Sirinukunwattana,
• Ruby Wood,
• Alan Aberdeen,
• Jens Rittscher,
• Olga K. Weinberg,
• Robert Hasserjian,
• Olga Pozdnyakova,
• Frank Peale,
• Brian Higgins,
• Pontus Lundberg,
• Kerstin Trunzer,
• Claire N. Harrison,
• Daniel Royston

Affiliations

Hosuk Ryou

Nuffield Department of Medicine University of Oxford Oxford UK

Korsuk Sirinukunwattana

Ground Truth Labs, Ltd. Oxford UK

Ruby Wood

Institute of Biomedical Engineering (IBME), Department of Engineering Science University of Oxford Oxford UK

Alan Aberdeen

Ground Truth Labs, Ltd. Oxford UK

Jens Rittscher

Ground Truth Labs, Ltd. Oxford UK

Olga K. Weinberg

Department of Pathology University of Texas Southwestern Medical Center Dallas Texas USA

Robert Hasserjian

Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA

Olga Pozdnyakova

Department of Pathology and Laboratory Medicine University of Pennsylvania Philadelphia Pennsylvania USA

Frank Peale

Genentech, Inc. South San Francisco California USA

Brian Higgins

Genentech, Inc. South San Francisco California USA

Pontus Lundberg

F. Hoffmann‐La Roche, Ltd. Basel Switzerland

Kerstin Trunzer

F. Hoffmann‐La Roche, Ltd. Basel Switzerland

Claire N. Harrison

Guy's & St Thomas' NHS Foundation Trust London UK

Daniel Royston

Nuffield Division of Clinical Laboratory Sciences (NDCLS), Radcliffe Department of Medicine University of Oxford Oxford UK